{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=metformin+%28Glucophage%E2%84%A2%29", "query": { "intervention": "metformin (Glucophage™)" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 23, "total_pages": 3, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=metformin+%28Glucophage%E2%84%A2%29&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-10-10T01:31:57.222Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT02100475", "title": "A Trial Comparing Sequential Addition of Insulin Aspart Versus Further Dose Increase With Insulin Degludec/Liraglutide in Subjects With Type 2 Diabetes Mellitus, Previously Treated With Insulin Degludec/Liraglutide and Metformin and in Need of Further Intensification", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Diabetes", "Diabetes Mellitus, Type 2" ], "interventions": [ { "name": "insulin degludec/liraglutide", "type": "DRUG" }, { "name": "insulin aspart", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novo Nordisk A/S", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 31, "start_date": "2014-04", "completion_date": "2015-04", "has_results": true, "last_update_posted_date": "2017-01-20", "last_synced_at": "2026-10-10T01:31:57.222Z", "location_count": 7, "location_summary": "Fresno, California • Fort Lauderdale, Florida • Gurnee, Illinois + 4 more", "locations": [ { "city": "Fresno", "state": "California" }, { "city": "Fort Lauderdale", "state": "Florida" }, { "city": "Gurnee", "state": "Illinois" }, { "city": "Lexington", "state": "Kentucky" }, { "city": "Slidell", "state": "Louisiana" } ], "official_url": "https://clinicaltrials.gov/study/NCT02100475" }, { "nct_id": "NCT02073227", "title": "A Bioequivalence Study of the Fixed Dose Combination Tablets of Canagliflozin and Metformin Extended Release (XR) With Respect to the Individual Components", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Healthy Volunteers" ], "interventions": [ { "name": "Canagliflozin, 300 mg", "type": "DRUG" }, { "name": "Metformin XR, 500 mg", "type": "DRUG" }, { "name": "CANA/MET XR FDC, Formulation 1, 150 mg/1,000 mg", "type": "DRUG" }, { "name": "CANA/MET XR FDC, Formulation 2, 150 mg/1,000 mg", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Janssen Research & Development, LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "55 Years", "sex": "ALL", "summary": "18 Years to 55 Years" }, "enrollment_count": 52, "start_date": "2014-02", "completion_date": "2014-06", "has_results": false, "last_update_posted_date": "2014-09-09", "last_synced_at": "2026-10-10T01:31:57.222Z", "location_count": 1, "location_summary": "Tempe, Arizona", "locations": [ { "city": "Tempe", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT02073227" }, { "nct_id": "NCT02681094", "title": "A Multi-Center, Randomized, Double-Blind, Phase III Trial to Evaluate the Safety and Efficacy of Saxagliptin Co-administered With Dapagliflozin Compared to Saxagliptin or Dapagliflozin All Given as add-on Therapy to Metformin in Subject With Type 2 Diabetes", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Type 2 Diabetes Mellitus", "Inadequate Glycaemic Control" ], "interventions": [ { "name": "Dapagliflozin", "type": "DRUG" }, { "name": "Placebo for Dapagliflozin", "type": "DRUG" }, { "name": "Saxagliptin", "type": "DRUG" }, { "name": "Placebo for Saxagliptin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AstraZeneca", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "130 Years", "sex": "ALL", "summary": "18 Years to 130 Years" }, "enrollment_count": 905, "start_date": "2016-02-26", "completion_date": "2017-07-15", "has_results": true, "last_update_posted_date": "2018-10-10", "last_synced_at": "2026-10-10T01:31:57.222Z", "location_count": 48, "location_summary": "Saraland, Alabama • Fresno, California • Harbor City, California + 41 more", "locations": [ { "city": "Saraland", "state": "Alabama" }, { "city": "Fresno", "state": "California" }, { "city": "Harbor City", "state": "California" }, { "city": "Hawaiian Gardens", "state": "California" }, { "city": "Lancaster", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02681094" }, { "nct_id": "NCT00835497", "title": "5 mg Glipizide/500 mg Metformin Hydrochloride Tablets, Fasting", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Healthy" ], "interventions": [ { "name": "5 mg/500 mg Glipizide Metformin Hydrochloride Tablets", "type": "DRUG" }, { "name": "5 mg/500 mg METAGLIP™ Tablets", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Teva Pharmaceuticals USA", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "45 Years", "sex": "ALL", "summary": "18 Years to 45 Years" }, "enrollment_count": 40, "start_date": "2004-06", "completion_date": "2004-06", "has_results": true, "last_update_posted_date": "2009-09-15", "last_synced_at": "2026-10-10T01:31:57.222Z", "location_count": 2, "location_summary": "East Grand Forks, Minnesota • Fargo, North Dakota", "locations": [ { "city": "East Grand Forks", "state": "Minnesota" }, { "city": "Fargo", "state": "North Dakota" } ], "official_url": "https://clinicaltrials.gov/study/NCT00835497" }, { "nct_id": "NCT03684642", "title": "Efficacy and Safety of Efpeglenatide Versus Dulaglutide in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Type 2 Diabetes Mellitus" ], "interventions": [ { "name": "Efpeglenatide", "type": "DRUG" }, { "name": "Dulaglutide", "type": "DRUG" }, { "name": "Background therapy Metformin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sanofi", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 908, "start_date": "2018-09-26", "completion_date": "2020-11-17", "has_results": true, "last_update_posted_date": "2021-11-01", "last_synced_at": "2026-10-10T01:31:57.222Z", "location_count": 30, "location_summary": "Birmingham, Alabama • Chandler, Arizona • Glendale, Arizona + 25 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Chandler", "state": "Arizona" }, { "city": "Glendale", "state": "Arizona" }, { "city": "Peoria", "state": "Arizona" }, { "city": "Huntington Park", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03684642" }, { "nct_id": "NCT02613897", "title": "ESR-15-11293 - Saxa/Dapa, Safety and Efficacy Study", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Diabetes Mellitus, Type 2" ], "interventions": [ { "name": "Saxagliptin", "type": "DRUG" }, { "name": "Dapagliflozin", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "The University of Texas Health Science Center at San Antonio", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "18 Years to 70 Years" }, "enrollment_count": 56, "start_date": "2016-01", "completion_date": "2018-06-30", "has_results": true, "last_update_posted_date": "2019-08-14", "last_synced_at": "2026-10-10T01:31:57.222Z", "location_count": 1, "location_summary": "San Antonio, Texas", "locations": [ { "city": "San Antonio", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT02613897" }, { "nct_id": "NCT00859898", "title": "Study of Dapagliflozin in Combination With Metformin XR to Initiate the Treatment of Type 2 Diabetes", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Type 2 Diabetes Mellitus" ], "interventions": [ { "name": "Dapagliflozin", "type": "DRUG" }, { "name": "Metformin XR", "type": "DRUG" }, { "name": "dapagliflozin matching Placebo", "type": "DRUG" }, { "name": "metformin HCl Modified Release matching Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AstraZeneca", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "77 Years", "sex": "ALL", "summary": "18 Years to 77 Years" }, "enrollment_count": 1093, "start_date": "2009-04", "completion_date": "2010-05", "has_results": true, "last_update_posted_date": "2016-07-07", "last_synced_at": "2026-10-10T01:31:57.222Z", "location_count": 64, "location_summary": "Ozark, Alabama • Tempe, Arizona • Concord, California + 53 more", "locations": [ { "city": "Ozark", "state": "Alabama" }, { "city": "Tempe", "state": "Arizona" }, { "city": "Tempe", "state": "Arizona" }, { "city": "Concord", "state": "California" }, { "city": "Encinitas", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00859898" }, { "nct_id": "NCT00834587", "title": "5 mg Glipizide/500 mg Metformin Hydrochloride Tablets, Non-Fasting", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Healthy" ], "interventions": [ { "name": "5 mg/500 mg METAGLIP™ Tablets", "type": "DRUG" }, { "name": "5 mg/500 mg Glipizide Metformin Hydrochloride Tablets", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Teva Pharmaceuticals USA", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "45 Years", "sex": "ALL", "summary": "18 Years to 45 Years" }, "enrollment_count": 40, "start_date": "2004-06", "completion_date": "2004-06", "has_results": true, "last_update_posted_date": "2009-09-15", "last_synced_at": "2026-10-10T01:31:57.222Z", "location_count": 2, "location_summary": "East Grand Forks, Minnesota • Fargo, North Dakota", "locations": [ { "city": "East Grand Forks", "state": "Minnesota" }, { "city": "Fargo", "state": "North Dakota" } ], "official_url": "https://clinicaltrials.gov/study/NCT00834587" }, { "nct_id": "NCT00760344", "title": "Efficacy and Safety of SYR-472 in Subjects With Type 2 Diabetes Mellitus", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Diabetes Mellitus" ], "interventions": [ { "name": "SYR-472", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "Sitagliptin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Takeda", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "18 Years to 80 Years" }, "enrollment_count": 386, "start_date": "2007-03", "completion_date": "2008-03", "has_results": false, "last_update_posted_date": "2016-06-22", "last_synced_at": "2026-10-10T01:31:57.222Z", "location_count": 105, "location_summary": "Birmingham, Alabama • Mobile, Alabama • Montgomery, Alabama + 102 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Mobile", "state": "Alabama" }, { "city": "Montgomery", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Tempe", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT00760344" }, { "nct_id": "NCT01068717", "title": "Bioequivalence Study of 2.5-mg Saxagliptin and 500-mg Glucophage in Tablets and a Fixed-dose Combination Tablet in Healthy Participants", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Type 2 Diabetes Mellitus" ], "interventions": [ { "name": "Saxagliptin, 2.5 mg + Metformin, 500 mg (fasted state)", "type": "DRUG" }, { "name": "Saxagliptin, 2.5 mg /Metformin, 500 mg FDC (fasted state)", "type": "DRUG" }, { "name": "Saxagliptin, 2.5 mg + Metformin, 500 mg (fed state)", "type": "DRUG" }, { "name": "Saxagliptin, 2.5 mg /Metformin, 500 mg FDC (fed state)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AstraZeneca", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "55 Years", "sex": "ALL", "summary": "18 Years to 55 Years" }, "enrollment_count": 27, "start_date": "2010-03", "completion_date": "2010-03", "has_results": true, "last_update_posted_date": "2015-05-12", "last_synced_at": "2026-10-10T01:31:57.222Z", "location_count": 1, "location_summary": "Austin, Texas", "locations": [ { "city": "Austin", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT01068717" } ] }